Uterine progesterone signaling is a target for metformin therapy in PCOS-like rats.

Hu M, Zhang Y, Feng J, Xu X, Zhang J, Zhao W, Guo X, Li J, Vestin E, Cui P, Li X, Wu XK, Brännström M, Shao LR, Billig H

J Endocrinol 237 (2) 123-137 [2018-05-00; online 2018-03-13]

Impaired progesterone (P4) signaling is linked to endometrial dysfunction and infertility in women with polycystic ovary syndrome (PCOS). Here, we report for the first time that elevated expression of progesterone receptor (PGR) isoforms A and B parallels increased estrogen receptor (ER) expression in PCOS-like rat uteri. The aberrant PGR-targeted gene expression in PCOS-like rats before and after implantation overlaps with dysregulated expression of Fkbp52 and Ncoa2, two genes that contribute to the development of uterine P4 resistance. In vivo and in vitro studies of the effects of metformin on the regulation of the uterine P4 signaling pathway under PCOS conditions showed that metformin directly inhibits the expression of PGR and ER along with the regulation of several genes that are targeted dependently or independently of PGR-mediated uterine implantation. Functionally, metformin treatment corrected the abnormal expression of cell-specific PGR and ER and some PGR-target genes in PCOS-like rats with implantation. Additionally, we documented how metformin contributes to the regulation of the PGR-associated MAPK/ERK/p38 signaling pathway in the PCOS-like rat uterus. Our data provide novel insights into how metformin therapy regulates uterine P4 signaling molecules under PCOS conditions.

Integrated Microscopy Technologies Gothenburg [Service]

QC bibliography QC xrefs

PubMed 29535146

DOI 10.1530/JOE-18-0086

Crossref 10.1530/JOE-18-0086

pii: JOE-18-0086